State lawmakers seeking to lower drug prices are zeroing in on rebates negotiated between pharmacy benefit managers and drug manufacturers in an opaque system they say steers profits to behind-the-scenes operators while patients bear the expense.
Rebates are among the latest areas of contention as state lawmakers, and now Congress as well, place pressure on pharmacy benefit managers — companies that contract with health plans to administer prescription drug benefits.
Already a subscriber? Sign in